34547-26-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Methoxy-benzeneacetic acid hydrazide is used as a nonsteroidal anti-inflammatory drug (NSAID) for the treatment of pain and inflammation associated with various conditions such as arthritis and muscle injuries. It is effective in reducing inflammation and pain by inhibiting the production of hormones that cause these symptoms.
Used in Pain Management:
Tolmetin is used as a pain management agent to alleviate discomfort and pain associated with different conditions. Its anti-inflammatory properties make it a suitable option for managing pain caused by inflammation.
Used in Inflammation Reduction:
2-Methoxy-benzeneacetic acid hydrazide is used to reduce inflammation in the body. By inhibiting the production of hormones that cause inflammation, it helps in managing inflammatory conditions effectively.

Upstream product

• 93-25-4 2-methoxyphenylacetic acid 
• 27798-60-3 methyl 2-(2-methoxyphenyl)acetate 
• 28033-63-8 2-(2-methoxyphenyl)acetyl chloride 

Downstream Products

• 1094435-24-1 C₁₀H₁₂N₄OS 
• 1394137-56-4 C₁₇H₁₃ClN₄OS 
• 1394137-57-5 C₁₇H₁₂F₂N₄OS 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of 3,4,5-trisubstituted-1,2,4-triazoles: High affinity and selective somatostatin receptor-4 agonists for Alzheimer's disease treatment

Somatostatin receptor-4 (SST4) is highly expressed in brain regions affiliated with learning and memory. SST4 agonist treatment may act to mitigate Alzheimer's disease (AD) pathology. An integrated approach to SST4 agonist lead optimization is presented herein. High affinity and selective agonists with biological efficacy were identified through iterative cycles of a structure-based design strategy encompassing computational methods, chemistry, and preclinical pharmacology. 1,2,4-Triazole derivatives of our previously reported hit (4) showed enhanced SST4 binding affinity, activity, and selectivity. Thirty-five compounds showed low nanomolar range SST4 binding affinity, 12 having a Ki 500-fold affinity for SST4 as compared to SST2A. SST4 activities were consistent with the respective SST4 binding affinities (EC50 600-fold selectivity over SST2A) display a favorable physiochemical profile, and was advanced to learning and memory behavior evaluations in the senescence accelerated mouse-prone 8 model of AD-related cognitive decline. Chronic administration enhanced learning with i.p. dosing (1 mg kg-1) compared to vehicle. Chronic administration enhanced memory with both i.p. (0.01, 0.1, 1 mg kg-1) and oral (0.01, 10 mg kg-1) dosing compared to vehicle. This study identified a novel series of SST4 agonists with high affinity, selectivity, and biological activity that may be useful in the treatment of AD. This journal is

3,4,5-TRISUBSTITUTED-1,2,4-TRIAZOLES AND 3,4,5-TRISUBSTITUTED-3-THIO-1,2,4-TRIAZOLES AND USES THEREOF

The present disclosure describes novel compounds that are somatostatin receptor type 4 agonists.

Novel triazole derivative with anti-inflammatory and anti-hyperglycemic activity and method for preparing the same

The present invention relates to a novel triazole derivative having anti-inflammatory and anti-diabetic activities, to a production method thereof, and to a pharmaceutical composition for preventing or treating inflammatory diseases and diabetic diseases, comprising the same. The novel triazole derivative according to the present invention has excellent inhibitory activity of type II collagen and COX-2 and exhibits anti-inflammatory activity, and thus can be used as a pharmaceutical composition for the preventing or treating inflammatory diseases. In addition, anti-diabetic activity is showed due to excellent inhibitory activities of alpha-glucosidase and alpha-amylase, thereby being able to be used as a pharmaceutical composition for preventing or treating diabetes diseases.COPYRIGHT KIPO 2017

Synthesis, structural elucidation and bioevaluation of 4-amino-1,2,4-triazole-3-thione's Schiff base derivatives

In this study, a series of ten triazole Schiff base derivatives 6a-j were synthesized through microwave assisted imine formation by reacting substituted amino triazole 5 with different substituted aldehydes. All the synthesized compounds were evaluated fo

O-methoxyphenylacetic acid Schiff base and synthesis method and application thereof

The invention relates to o-methoxyphenylacetic acid Schiff base and a synthetic method and an application thereof, wherein R1 represents hydrogen, hydroxyl, nitryl or bromine, R2 represents hydrogen or nitryle, and R3 represents hydrogen, methoxyl, nitryl, chlorine or hydroxyl. The compound provided by the invention has remarkable inhibiting effect on escherichia coli, staphylococcus aureus, Bacillus subtilis and Pseudomonas aeruginosa, and the minimal inhibitory concentration can reach 12.5 microgram/mL, so that the compound can be used as a bacteriostatic agent.

Acetylcholinesterase inhibition activity of some quinolinyl substituted triazolothiadiazole derivatives

A series of aralkanoic acids was converted into aralkanoic acid hydrazides through their esters formation. The aralkanoic acid hydrazides upon treatment with carbon disulfide and methanolic potassium hydroxide yielded potassium dithiocarbazinate salts, which on refluxing with aqueous hydrazine hydrate yielded 5-aralkyl-4-amino-3-mercapto-1,2,4-triazoles. The target compounds, 3-aralkyl-6-(substitutedquinolinyl) [1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles, were synthesized by condensing various quinolinyl substituted carboxylic acids with 5-aralkyl-4-amino-3-mercapto-1,2,4-triazoles in phosphorus oxychloride. The structures of the newly synthesized triazolothiadiazoles were characterized by IR, 1H NMR, 13C NMR, and elemental analysis studies. The structure of one of the 5-aralkyl-4-amino-3-mercapto-1,2,4-triazoles was unambiguously deduced by single crystal X-ray diffraction analysis. All the synthesized compounds were screened for their acetylcholinesterase inhibition activities. Four of the triazolothiadiazoles exhibited excellent acetylcholinesterase inhibition activities as compared to the reference inhibitor.

Synthesis, crystal structure, anti-inflammatory and anti-hyperglycemic activities of novel 3,4-disubstituted 1,2,4-triazol-5(4H)-one derivatives

A new series of 3,4-disubstituted 1,2,4-triazol-5(4H)-one 5a-r, bearing various methoxyphenyl, fluorophenyl, tolyl and phenyl groups, was synthesized by the dehydrocyclization of hydrazinecarboxamides 4a-r by refluxing in a 2 N sodium hydroxide solution. Hydrazinecarboxamides 4a-r was synthesized via the condensation of the corresponding aralkanoic acid hydrazides, 3a-g, with fluoro-, tolyl- and methoxyphenylisocyanates. The newly synthesized compounds (5ar) were characterized by IR, 1H NMR and 13C NMR analyses. The structure of one compound 5a was determined by single crystal X-ray diffraction analysis. All of the synthesized compounds were screened for their anti-inflammatory and anti-diabetic (α-glucosidase and α-amylase inhibition) activity to identify new drugs that might be useful in preventing damage related to diabetes and inflammation. Compounds 5j, 5k and 5m decrease the expression of type II collagen in a dose dependent manner; similarly 5l decrease the COX-2 expression of rabbit articular chondrocytes in a dose dependent manner possessing potent anti-inflammatory potential while some of derivatives including 5c, 5e, 5g and 5h cause inflammation. Meanwhile, excellent α-glucosidase and moderate α-amylase inhibitory profiles against carbohydrate modulating enzymes were demonstrated by compounds 5b, 5f, 5k and 5q compared to the reference standard acarbose, and compounds 5g, 5h, 5i, 5j, 5l and 5o exhibited moderate to low enzyme inhibition potential among the series.

Similarities and differences in the crystal packing of methoxybenzyl and methoxyphenylethyl-1,3,4-oxadiazole-2(3H)-thiones

This work reports the crystal and molecular structures of five 1,3,4-oxadiazol-2(3H)-thiones derived from 2, 3 and 4-methoxy substituted 2-phenylacetic acid and 2- and 4-methoxy substituted 3-phenylpropanoic acid. The methoxybenzyl-1,3,4-oxadiazol-2(3H)-thiones are V-shaped while the corresponding methoxyphenylethyl-systems are close to planar, which impacts the solid state molecular packing arrangement. For molecules 1-4, inversion related N-H...S hydrogen bonds generating R22(8) rings dominate the packing, supported by an eclectic mix of C-H...O, C-H...S, C-H...π and π...π contacts that stack the molecules into interconnected columns. In contrast, each of the two unique molecules in the asymmetric unit of 5 forms N-H...O contacts with like molecules augmented by C-H...S contacts for one molecule and C-H...O contacts for the other to generate planar layers that are interconnected though a series of π...π stacking interactions. The Royal Society of Chemistry.

Synthesis, urease inhibition, antioxidant and antibacterial studies of some 4-Amino-5-aryl-3H-1,2,4-triazole-3-thiones and their 3,6-Disubstituted 1,2,4-Triazolo[3,4-b]1,3,4-thiadiazole derivatives

A new series of 4-amino-5-aryl-3H-1,2,4-triazole-3-thiones, bearing various methoxybenzyl- and methoxyphenethyl groups, was synthesized by refluxing potassium hydrazinecarbodithioate salts in dilute aqueous solution of hydrazine hydrate. These salts were formed by the reaction of acid hydrazides and carbon disulfide in methanolic potassium hydroxide solution at 0-5 °C. 4-Amino-5-aryl-3H-1,2,4-triazole-3-thiones were condensed with different substituted aromatic acids to yield 3,6-disubstituted-1,2,4-triazolo[3,4-b]1,3, 4-thiadiazoles. The structures of the synthesized compounds were characterized by infrared (IR), 1H and 13C nuclear magnetic resonance (NMR), elemental analysis and mass spectrometric (MS) studies. All the synthesized compounds were screened for their urease inhibition, antioxidant and antibacterial activities. Some compounds showed excellent urease inhibition activity, more than the standard drug. Others exhibited potent antioxidant activity. All the compounds showed significant antibacterial activities as compared to the standard drug.

Synthesis, crystal structure and b-glucuronidase inhibition activity of some new hydrazinecarboxamides and their 1,2,4-triazole derivatives

A new series of hydrazinecarboxamides (5a-n), bearing various methoxyphenyl and methoxyphenethyl groups, was synthesized by condensation of corresponding acid hydrazides (3a-f) with methoxyphenylisocyanates (4a-c). Dehydrocyclization of hydrazinecarboxamides (5a-n) yielded corresponding methoxyphenyl and methoxyphenethyl substituted triazoles (6a-l) by refluxing in 2 N aqueous sodium hydroxide solution. All the synthesized compounds were screened for their b-glucuronidase inhibition activity. Compounds 5a, 5e, 5h, and 5l exhibited an excellent b-glucuronidase inhibitory activity as compared to the standard inhibitor. Springer Science+Business Media, LLC 2011.